Foghorn Therapeutics Inc (FHTX) — Cash Flow-to-Debt Ratio
Foghorn Therapeutics Inc (FHTX) has a Cash Flow-to-Debt Ratio of -0.07x as of December 2025, meaning its operating cash flow of $-22.27 Million could theoretically repay 0% of its total liabilities ($306.60 Million) in one year. See FHTX cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Foghorn Therapeutics Inc Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for Foghorn Therapeutics Inc across 8 annual periods. Also explore how fast is Foghorn Therapeutics Inc growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Foghorn Therapeutics Inc (2018–2025)
Year-by-year debt coverage analysis for Foghorn Therapeutics Inc. For market capitalisation and broader financial context, see market cap of Foghorn Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.28x | $-86.10 Million | $306.60 Million | ▲ +7.8% |
| 2024 | -0.30x | $-100.41 Million | $329.51 Million | ▲ +6.3% |
| 2023 | -0.33x | $-118.11 Million | $363.11 Million | ▼ -168.0% |
| 2022 | 0.48x | $193.61 Million | $404.77 Million | ▲ +502.6% |
| 2021 | -0.12x | $-50.25 Million | $422.90 Million | ▲ +58.4% |
| 2020 | -0.29x | $-31.29 Million | $109.41 Million | ▲ +31.9% |
| 2019 | -0.42x | $-46.34 Million | $110.36 Million | ▼ -52.6% |
| 2018 | -0.28x | $-22.65 Million | $82.33 Million | — |